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Abstract
Background: Previous studies have suggested that concomitant mitral regurgitation (MR) is a risk factor for acute
transcatheter aortic valve implantation (TAVI) failure, but may improve afterwards. Aim of this study was to assess
the prevalence, clinical meaning and modifications of MR in patients undergoing TAVI.
Methods: In a retrospective, two-center (Potenza-San Carlo and Roma- San Camillo) study, from January 2010 to
June 2014 we enrolled 165 consecutive patients (age =80 ± 5 years, 74 males, Ejection Fraction 51 ± 9 %) referred
for TAVI with either Medtronic Core-ReValving System (in 114 patients, 69 %) or balloon-expandable Edwards
SAPIEN/SAPIEN XT (in 51 patients, 31 %). All patients underwent TTE and TEE assessment of MR (from 1, mild to
4 = severe according to ESC latest guidelines) with core lab reading by a single observer blinded to patient identity
and status. Assessment was performed at baseline (24 h prior to intervention) and at 1, 6, 12 and 24 months.
Results: Mild-to-Moderate MR (grade 1–2) was present in 137 patients and Moderate-to-Severe MR (grade 3–4) was
present in 28 patients. No significant differences were seen comparing perioperative mortality and morbidity
between the two groups. In the group of preoperative MR grade 3–4 the mean decrease from MR pre-TAVI to MR
at 1 month post-TAVI was 0.464 (p < 0.0001) and this improvement was persistent at 6 months (p < 0.0001) and at
12 months (p < 0.0001), with partial benefit loss at 1 and 2 years. The mean difference from Left Atrial volume post-
TAVI at 1 month was 16.5 ml (p < 0.0001) and this improvement was persistent at 12 months 12.12 ml (p < 0.0001).
Conclusions: TAVI effectively treats the aortic valve but as a beneficial by product also ameliorates concomitant
MR. The presence of moderate-to-severe MR does not increase the acute risk of failure of TAVI. In successful
procedures, the MR improves immediately and persistently.
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Background
Mitral regurgitation (MR) is a common finding in pa-
tients with aortic stenosis (AS). At the time of aortic
valve replacement (AVR) up to two thirds of patients
with AS have varying degrees of MR [1]. Most published
studies on valvular heart disease have focused on either
regurgitant or stenotic single valve disease. Data on
multi-valve disease are scarce. As result, North Ameri-
can and European guidelines offer limited insight with
respect to management of multivalve disease. Those
recommendations that are made are largely based on
small studies or on expert consensus opinion (Grade C).
A decrease in MR severity is common following iso-
lated AVR [2–4]. Early improvement might result from
acute reverse left ventricular (LV), including a reduction
in LV end-diastolic volume and a decrease in mitral
tethering forces [5, 6].
Transcatheter valve therapies are a feasible alternative
to conventional open-heart surgery in many patients
with valvular disease. For AS, transcatheter aortic valve
implantation (TAVI) is the standard of care in inoperable
patients and an alternative to SVAR in high-surgical risk
patients [7–13]. However , TAVI is still a relatively novel
technology, and short and long term morbidity and
mortality after TAVI remain significant [14]. There is
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substantial interest in the identification and modification
of factors influencing morbidity and mortality after
TAVI.
Recently, Chakravarty et al. [14], have reported that
moderate-severe MR is present in 20 % to 30 % of pa-
tients who underwent TAVI and constitutes a significant
coexisting valvular heart disease burden [15–21]. In this
meta-analysis, the severity of MR improved after TAVI
in 61 ± 6.0 % of patients, but baseline moderate-severe
MR and significant residual MR after TAVI are associ-
ated with an increase in mortality after TAVI and repre-
sent an important group to target with medical or
transcatheter therapies in the future [14]. Therefore the
aim of this retrospective, observational, two-center study
was to evaluate the improvement of mitral regurgitation
in patients undergoing TAVI with concomitant MR.
Methods
Study design and patient population
From January 2010 to June 2014, 165 consecutive pa-
tients affected by severe aortic stenosis underwent TAVI
either using Medtronic Core-ReValving System (in 114
patients, 69 %) or using balloon-expandable Edwards
SAPIEN/SAPIEN XT (in 51 patients, 31 %) at Potenza-
San Carlo Hospital and Roma-San Camillo Hospital.
All patients were evaluated for TAVI by the local heart
team, which included a clinical cardiologist, an interven-
tional cardiologist, a cardiac surgeon, and a cardiac
anesthesiologist. The evaluation of the heart team led to
the indication for TAVI after careful assessment of all
the clinical/anatomic conditions determining a higher
risk of mortality/morbidity after surgery. In all patients
scheduled for TAVI who gave written consent for the
procedure follow-up was scheduled at 1, 6, 12 and
24 months. Patients were followed up by means of out-
patient clinics and regular contact with clinical cardiolo-
gist. At any follow-up time all patients are underwent a
clinical exam and echocardiographic study.
To define the events in the follow-up we referred to
the current standard for definition of the events in TAVI
represented by VARC-2 criteria [22].
Device and procedure
Arterial access (femoral,radial), percutaneous puncture,
or surgical exposure was also determined
on the basis of the panel of preoperative imaging tests,
which included in all cases both angiography and com-
puted tomography scan. After the procedure, all patients
were managed in an intensive care unit or coronary care
unit for at least one day.
Data collection and definitions
Transthoracic and TEE echocardiography was performed
before TAVI, after TAVI, and at 1, 6, 12 and 24 months by
a senior cardiologist. MR severity was graded as no/mild
(0/1), moderate (2), moderate-severe(3) or severe (4), [23].
Mitral annular calcification, prolapse and thickening was
reported according to the guidelines [23]. MR type has
been classified as organic (primary) or functional (second-
ary). Organic MR is attributable to intrinsic valvular dis-
ease, whereas functional MR is caused by regional or
global left ventricle (LV) remodeling without structural
abnormalities of the valve apparatus. A medical record
reporting a fatality was available in 13 patients (7.9 %);
echocardiographic follow-up was available in 152 patients.
Basal characteristic of overall population are shown in
Table 1.
Statistical analysis
Categorical variables were presented as absolute num-
bers and percentages and compared using chi-square
test. Continuous variables were presented as mean ±
standard deviation and were compared using t-test.
For echocardiographic data, a two way analysis for re-
peated measures (between the two groups and among
different times) was performed using the Linear Mixed
Model; individual comparison between groups for each
parameter at different times was carried using unpaired
t-test with post-hoc Bonferroni correction.
Kaplan and Meier curves were used to calculate the
survival probability. Cox proportional hazard model was
instead used to perform univariate analysis of mortality.
Since only a single factor (female sex) was found to have
a p value ≤ 0.10, multivariate analysis could not be
carried.
All P values reported are 2 sided, and a value of P <
0.05 was considered significant. All data were processed
with the Statistical Package for Social Sciences, version
21 (SPSS, Chicago, IL).
Results
Moderate-Severe MR (Grade 3–4) at the time of the
procedure was present in 28 pts (17 %).
Mild-Moderate MR (Grade 1–2) was present in 137
pts (83 %).
Patients with concomitant grade 3–4 MR appear quite
different from patients with grade 1–2 MR.
Patients with Moderate-Severe MR (Grade 3–4) had a
lower LV function compared with patients with Mild-
Moderate MR (Grade 1–2) (39.8 ± 7.5 % versus 53.2 ±
7.9 %; p < 0.0001), a lower trans-aortic Mean gradient
(39.5 ± 10.5 mmHg versus 45.8 ± 7.2 mmHg; p = 0.002)
and a lower trans-aortic Peak gradient (63.8 ±
20.8 mmHg versus 77.9 ± 15.7 mmHg; p < 0.0001).
In patients with grade 3–4 MR, the aetiology of mitral
valve disease is predominantly functional (75 %) as also
confirmed by the significantly lower incidence of
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Table 1 Basal characteristic of overall population according to MR grade groups
All Preoperative MR Preoperative MR p value
Grade 3–4 Grade 1–2
Patients 165 28 137
Demographics
Males 74 (44.8 %) 19 (67.9 %) 55 (40.1 %) 0.01
Mean Age (years) 80.2 ± 5.6 81 ± 5.2 79.9 ± 5.6 0.38
Weight (kg) 67.1 ± 10.8 71.6 ± 7.2 66.2 ± 11.1 0.01
Height (m) 1.62 ± 0.07 1.67 ± 0.05 1.61 ± 0.08 0.0005
Body surface area (m2) 1.7 ± 0.2 1.81 ± 0.08 1.69 ± 0.16 0.0005
Ejection Fraction (%) 51 ± 9.3 39.8 ± 7.5 53.2 ± 7.9 <0.0001
Aortic valve
Peak gradient (mmHg) 75.5 ± 17.5 63.8 ± 20.8 77.9 ± 15.7 <0.0001
Mean gradient (mmHg) 44.8 ± 8.2 39.5 ± 10.5 45.8 ± 7.2 0.0002
Aortic valve area (cm2) 0.59 ± 0.9 0.58 ± 0.08 0.6 ± 0.1 0.34
Mitral valve
MR mechanism
Degenerative 118 (71.5 %) 7 (25 %) 111 (81 %) <0.0001
Functional 47 (28.5 %) 21 (75 %) 26 (19 %) <0.0001
Leaflets disease
Calcifications 55 (33.3 %) 2 (7.1 %) 53 (38.7 %) 0.0008
Thickening 63 (38.2 %) 5 (17.9 %) 58 (42.3 %) 0.02
Prolapse 7 (4.2 %) 2 (7.1 %) 5 (3.6 %) 0.33
Mitral regurgitation [1–4] 1.9 ± 0.7 3.1 ± 0.3 1.6 ± 0.5 <0.0001
MR grade I 54 (32.7 %) 54 (192.9 %) 0 (0 %) n.c
MR grade II 83 (50.3 %) 83 (296.4 %) 0 (0 %) n.c.
MR grade III 25 (15.2 %) 0 (0 %) 25 (18.2 %) n.c.
MR grade IV 3 (1.8 %) 0 (0 %) 3 (2.2 %) n.c.
EROA (mm2) 24.9 ± 8 38.5 ± 6.7 22.1 ± 4.7 <0.0001
Vena contracta (mm) 36.1 ± 11.8 55.4 ± 9.4 32.1 ± .7.5 <0.0001
Regurgitant volume (ml) 35.1 ± 10.2 50.8 ± 7 31.9 ± 7.3 <0.0001
Regurgitant fraction (%) 33.6 ± 9.9 48.6 ± 6.4 30.4 ± 7.2 <0.0001
LA volume (ml) 64.2 ± 14.3 79.6 ± 17.7 61 ± 11.1 <0.0001
Procedure
Prosthesis model
Corevalve 114 (69.1 %) 19 (67.9 %) 95 (69.3 %) 0.99
Sapien 51 (30.9 %) 9 (32.1 %) 42 (30.7 %) 0.99
Valve size (mm) 26.8 ± 2.5 27.8 ± 2.3 26.6 ± 2.4 0.02
Table 2 Post operative results, according to MR grade groups
All Preoperative MR Preoperative MR p value
Grade 3–4 Grade 1–2
Patients 165 28 137
30 days mortality 3 (1.8 %) 0 3 (2.1 %) 0.99
Bleeding 6 (3.6 %) 2 (7.1 %) 4 (2.9 %) 0.26
Neurological complications 7 (4.2 %) 0 7 (5.1 %) 0.60
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structural changes of the mitral leaflets (Calcifications
7.1 % and Thickening 17.9 %).
Although preoperative characteristics are different,
there aren’t statistically significant differences, as
shown in Table 2, regarding mortality at 30 days be-
tween two groups (3 patients, 2.1 % for MR grade 1–
2 group and 0 patients, 0 % for MR grade 3–4 group;
p = 0.99) and incidence of peri-procedure complica-
tions: bleeding (4 patients, 2.9 % for MR grade 1–2
group and 2 patients, 7.1 % for MR grade 3–4 group;
p = 0.26); neurological complications (7 patients, 5.1 %
for MR grade 1–2 group and 0 patients, 0 % for MR
grade 3–4 group; p = 0.60).
Analysis of echocardiographic parameters
In the overall population, MR score went from 2.1 ±
0.6 to 1.6 ± 0.8 (p < 0.001) at the end of follow-up.
Figure 1 depicts the comparison between the two
study groups regarding the degree of MR before and
following TAVI up to two years: two way repeated
analysis showed a significant difference on the degree
of MR between the groups (F = 573.1; p < 0.001) and
across the different times (F = 72.3; p < 0.0001). For
the group with preoperative MR grade 1–2 no signifi-
cant difference was noted comparing the degree of
preoperative MR with any of the postoperative
timeframes.
In the group with preoperative MR grade 3–4 the
mean decrease from MR pre-TAVI to MR at 1 month
post-TAVI was 0.464 (p < 0.0001) and this improvement
was persistent at 6 months (p < 0.0001), 12 months (p <
0.0001) and 24 months (p < 0.0001), with partial benefit
loss at 1 and 2 years (Fig. 1).
Figure 2 depicts the comparison between the two
study groups regarding the degree of Vena Contracta
(VC) before and following TAVI up to two years: two
way repeated analysis showed a significant difference on
the degree of VC between the groups (F = 431.0; p <
0.001) and across the different times (F = 6.4; p =
0.0005). For the group with preoperative MR grade 1–2
no significant difference was noted comparing the de-
gree of preoperative VC with any of the postoperative
timeframes.
In the group with preoperative MR grade 3–4 the
mean decrease from VC pre-TAVI to VC at 1 month
post-TAVI was 4.1 mm (p < 0.0001) and this improve-
ment was persistent at 6 months , 14.4 mm (p < 0.0001),
Fig. 1 Different value of degree of mitral regurgitation at 0, 6, 12 and 24 months of follow-up in the two groups
Fig. 2 Different value of MR Vena Contracta (VC) at 0, 6, 12 and 24 months of follow-up in the two groups
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12 months (p < 0.0001) and 24 months (p < 0.0001),
(Fig. 2).
Figure 3 depicts the comparison between the two
study groups regarding the degree of EROA before and
following TAVI up to two years: two way repeated ana-
lysis showed a significant difference on the degree of
EROA between the groups (F = 477.5; p < 0.001) and
across the different times (F = 8.9; p < 0.0001). For the
group with preoperative MR grade 1–2 no significant
difference was noted comparing the degree of preopera-
tive EROA with any of the postoperative timeframes.
In the group with preoperative MR grade 3–4 the
mean decrease from EROA pre-TAVI to EROA at
1 month post-TAVI was 3.42 mm2 (p < 0.0001) and this
improvement was persistent at 6 months (p < 0.0001),
12 months (p < 0.0001) and 24 months (p < 0.0001),
(Fig. 3).
Figure 4 depicts the comparison between the two
study groups regarding the degree of Regurgitant frac-
tion (RF) before and following TAVI up to two years:
two way repeated analysis showed a significant differ-
ence on the degree of RF between the groups (F = 285.2;
p < 0.001) and across the different times (F = 68.3; p <
0.0001). For the group with preoperative MR grade 1–2
no significant difference was noted comparing the de-
gree of preoperative RF with any of the postoperative
timeframes.
In the group with preoperative MR grade 3–4 the
mean decrease from RF pre-TAVI to RF at 1 month
post-TAVI was 7.5 % (p < 0.0001) and this improvement
was persistent at 6 months (p < 0.0001), 12 months (p <
0.0001) and 24 months (p < 0.0001), (Fig. 4).
Figure 5 depicts the comparison between the two
study groups regarding the degree of Regurgitant volume
(RV) before and following TAVI up to two years: two
way repeated analysis showed a significant difference on
the degree of RV between the groups (F = 284.4; p <
0.001) and across the different times (F = 35.9; p <
0.0001). For the group with preoperative MR grade 1–2
no significant difference was noted comparing the de-
gree of preoperative RV with any of the postoperative
timeframes.
In the group with preoperative MR grade 3–4 the
mean decrease from RV pre-TAVI to RV at 1 month
Fig. 3 Different value of MR EROA at 0, 6, 12 and 24 months of follow-up in the two groups
Fig. 4 Different value of MR Regurgitant Fraction (RF) at 0, 6, 12 and 24 months of follow-up in the two groups
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post-TAVI was 6.2 (p < 0.0001) and this improvement
was persistent at 6 months (p < 0.0001), 12 months (p <
0.0001) and 24 months (p < 0.0001), (Fig. 5).
Figure 6 depicts the comparison between the two
study groups regarding the Left atrial volume (LA) of
MR before and following TAVI up to two years: two way
repeated analysis showed a significant difference on the
degree of LA between the groups (F = 103.4; p < 0.001)
and across the different times (F = 33.7; p < 0.0001). For
the group with preoperative MR grade 1–2 no signifi-
cant difference was noted comparing the degree of pre-
operative LA with any of the postoperative timeframes.
In the group with preoperative LA grade 3–4 the
mean decrease from LA pre-TAVI to MR at 1 month
post-TAVI was 16.5 (p < 0.0001) and this improvement
was persistent at 6 months (p < 0.0001), 12 months (p <
0.0001) and 24 months (p < 0.0001), (Fig. 6).
Follow-up survival
The mean follow-up was 1.1 ± 0.6 years and all patients
(100 %) completed at the follow-up.
Figure 7 shows the 2 years survival curve for both
groups: 6 months of 94.5 ± 1.8 %, at 12 months of 90.9 ±
2.5 % and 24 months of 90.0 ± 2.5 %. The follow up mor-
tality (10 patients, 6.0 %) occurred exclusively in the
grade 1–2 MR group. Cox hazard model showed that
the only predictive factor of follow-up mortality was fe-
male sex (HR:11.5, 95 % CI:1.4-85.2, p = 0.02).
Discussion
Compared with patients with mild baseline MR, those
with moderate or severe MR have a worse baseline clin-
ical characteristics (Low EF, Dilated LV), but post-
procedural mortality and morbidity are similar in two
groups. In fact, in patients with moderate or severe base-
line MR, the MR severity improves in post procedural
follow-up by overall echo-indices (vena contracta,
Regurgitant volume, Regurgitant fraction) : in 24 months
follow-up the post procedural values are lower than pre-
procedural status.
The presence of 2 different devices might add com-
plexity to the interpretation of the scenario. It has been
postulated that differences in the structure of the 2 de-
vices (Core Valve and Sapien) may imply a different risk
of mitral valve dysfunction; in other words, the longer
nitinol frame of the Core Valve could mechanically
Fig. 5 Different value of MR Regurgitant Volume (RV) at 0, 6, 12 and 24 months of follow-up in the two groups
Fig. 6 Different value of Left Atrial Volume (ml) at 0, 6, 12 and 24 months of follow-up in the two groups
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interfere with the anterior leaflet of the mitral apparatus,
especially in the presence of a low implantation [24].
Our data actually rule out this phenomenon because the
incidence of worsened MR was quite low and no differ-
ence was observed in the low implantation rate between
those with and those without a worsened MR. Similarly
there are no differences, in our population, between or-
ganic and functional MR.
About follow-up survival, our data showed that female
sex was the only predictive factor of mortality. This is
not surprising since 12 out 13 deaths were females.
Few and contrasting results have been reported in the
literature in terms of the prognostic significance and
magnitude of MR changes following TAVI. A sub-
analysis of the PARTNER trial [25] reported that pre-
operative moderate or severe MR (mostly moderate) was
associated with increased two-year mortality after surgi-
cal AVR, but not after TAVI, suggesting that TAVI may
be a reasonable option in selected high-risk patients with
combined aortic and mitral valve disease. As with the
PARTNER sub-analysis, D’Onofrio et al. [26] found that
moderate or severe MR did not appear to be a signifi-
cant risk factor for in-hospital mortality after TAVI. In
contrast, Toggweiler et al. [27] found that moderate or
severe MR in patients undergoing TAVI was associated
with a higher early, but not late, mortality rate.
The results of our study are consistent with the previ-
ous literature. Recently a meta-analysis of 8 studies in-
volving 8927 patients [14] evaluating the impact of MR
on outcomes after TAVI found that (a) significant MR at
baseline is associated with increased mortality after
TAVI; (b) the cause of MR (functional or degenerative)
or the type of transcatheter heart valve (Edwards valve
or CoreValve) does not affect mor- tality after TAVI; (c)
MR severity improves in up to 2/3 of patients after
TAVI; and (d) moderate-severe residual MR is associated
with increased mortality after TAVI.
The mechanism of improvement in MR severity is
clearly multifactorial [17]. The improved aortic valve
performance, with the subsequent reduction of the after-
load, is conceivably expected to reduce the pathological
retrograde flow through the mitral valve. It can also be
presumed that the resolution of aortic stenosis may fa-
cilitate the achievement of a better hemodynamic bal-
ance by reducing the neurohormonal activation caused
by the heart failure status. The treatment of the aortic
stenosis may also contribute to the restoration of the
proper geometry of the LV contraction, which may in
turn contribute to improved function of the mitral valve
apparatus, in particular when the concomitant MR is a
functional type.
Conclusions
TAVI effectively treats the aortic valve but as a beneficial
by product also ameliorates concomitant MR. The pres-
ence of moderate-to-severe MR does not increase the
acute risk of failure of TAVI. In successful procedures,
the MR improves immediately and persistently.
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